These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33201337)

  • 1. microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy.
    Galore-Haskel G; Greenberg E; Yahav I; Markovits E; Ortenberg R; Shapira-Fromer R; Itzhaki O; Schachter J; Besser MJ; Markel G
    Cancer Immunol Immunother; 2021 Jun; 70(6):1541-1555. PubMed ID: 33201337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
    Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.
    Kristensen NP; Heeke C; Tvingsholm SA; Borch A; Draghi A; Crowther MD; Carri I; Munk KK; Holm JS; Bjerregaard AM; Bentzen AK; Marquard AM; Szallasi Z; McGranahan N; Andersen R; Nielsen M; Jönsson GB; Donia M; Svane IM; Hadrup SR
    J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 34813506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma.
    Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US
    World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue biomarkers in melanoma patients treated with TIL.
    Knol AC; Nguyen JM; Pandolfino MC; Quéreux G; Brocard A; Peuvrel L; Saint-Jean M; Saiagh S; Khammari A; Dréno B
    PLoS One; 2012; 7(12):e48729. PubMed ID: 23284620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
    Radvanyi LG; Bernatchez C; Zhang M; Fox PS; Miller P; Chacon J; Wu R; Lizee G; Mahoney S; Alvarado G; Glass M; Johnson VE; McMannis JD; Shpall E; Prieto V; Papadopoulos N; Kim K; Homsi J; Bedikian A; Hwu WJ; Patel S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Davies MA; Mansaray R; Fulbright OJ; Toth C; Ramachandran R; Wardell S; Gonzalez A; Hwu P
    Clin Cancer Res; 2012 Dec; 18(24):6758-70. PubMed ID: 23032743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
    Forget MA; Haymaker C; Hess KR; Meng YJ; Creasy C; Karpinets T; Fulbright OJ; Roszik J; Woodman SE; Kim YU; Sakellariou-Thompson D; Bhatta A; Wahl A; Flores E; Thorsen ST; Tavera RJ; Ramachandran R; Gonzalez AM; Toth CL; Wardell S; Mansaray R; Patel V; Carpio DJ; Vaughn C; Farinas CM; Velasquez PG; Hwu WJ; Patel SP; Davies MA; Diab A; Glitza IC; Tawbi H; Wong MK; Cain S; Ross MI; Lee JE; Gershenwald JE; Lucci A; Royal R; Cormier JN; Wargo JA; Radvanyi LG; Torres-Cabala CA; Beroukhim R; Hwu P; Amaria RN; Bernatchez C
    Clin Cancer Res; 2018 Sep; 24(18):4416-4428. PubMed ID: 29848573
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanoma.
    Weiss SA; Han SW; Lui K; Tchack J; Shapiro R; Berman R; Zhong J; Krogsgaard M; Osman I; Darvishian F
    Hum Pathol; 2016 Nov; 57():116-125. PubMed ID: 27473267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
    Hanniford D; Zhong J; Koetz L; Gaziel-Sovran A; Lackaye DJ; Shang S; Pavlick A; Shapiro R; Berman R; Darvishian F; Shao Y; Osman I; Hernando E
    Clin Cancer Res; 2015 Nov; 21(21):4903-12. PubMed ID: 26089374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
    J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
    Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
    Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
    Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
    PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.
    Arienti F; Belli F; Rivoltini L; Gambacorti-Passerini C; Furlan L; Mascheroni L; Prada A; Rizzi M; Marchesi E; Vaglini M
    Cancer Immunol Immunother; 1993 May; 36(5):315-22. PubMed ID: 8477417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen-specific CD4
    Hall MS; Teer JK; Yu X; Branthoover H; Snedal S; Rodriguez-Valentin M; Nagle L; Scott E; Schachner B; Innamarato P; Hall AM; Blauvelt J; Rich CJ; Richards AD; Ceccarelli J; Langer TJ; Yoder SJ; Beatty MS; Cox CA; Messina JL; Abate-Daga D; Mule JJ; Mullinax JE; Sarnaik AA; Pilon-Thomas S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37802604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.